GENPF OTC
Genix Pharmaceuticals Corporation
1W: +0.0%
1M: +0.0%
3M: -8.6%
YTD: -54.0%
1Y: +0.0%
3Y: -90.6%
$0.01
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
-$1K
-187.2% ▼
Operating Income
-$153K
+36.4% ▲
Net Income
-$335K
-357.7% ▼
EPS (Diluted)
$-0.01
-366.7% ▼
EBITDA
-$152K
-410.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $12K | $4K | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | -67.2% | -100.0% |
| Cost of Revenue | $537K | $564K | $9K | $3K | $1K |
| Gross Profit | -$537K | -$564K | $3K | $1K | -$1K |
| Gross Margin | — | — | 26.4% | 32.0% | — |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1M | $434K | $279K | $174K | $152K |
| Operating Expenses | $2M | $1M | $884K | $242K | $152K |
| Operating Income | -$2M | -$1M | -$881K | -$241K | -$153K |
| Operating Margin | — | — | -7134.5% | -5949.2% | — |
| Interest Expense | $4K | $12K | $52K | $121K | $173K |
| Income Before Tax | -$2M | -$1M | -$4M | -$73K | -$335K |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$2M | -$1M | -$4M | -$73K | -$335K |
| Net Margin | — | — | -35600.3% | -1806.9% | — |
| EPS (Diluted) | $-0.03 | $-0.02 | $-0.07 | $-0.00 | $-0.01 |
| EBITDA | -$1M | -$434K | -$4M | $49K | -$152K |
| Shares Outstanding | 59M | 59M | 59M | 59M | 60M |